Corcept Therapeutics Incorporated Overview
Pro stress-test →Corcept is a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The company has commercialized Korlym for Cushing's syndrome, which generated significant revenue growth in 2025, while advancing a pipeline of selective cortisol modulators.
Strategic Profile
Pro stress-test →In 2025, the company's Cushing's syndrome business experienced a surge in demand with record new prescriptions and new prescribers, translating to a 37 percent increase in tablets sold compared to the prior year. The company has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone, backed by extensive intellectual property.
Competitive Landscape
Pro stress-test →Competitors include companies like Vanda Pharmaceuticals, Axsome Therapeutics, Outlook Therapeutics, Praxis Precision Medicines, and Sarepta Therapeutics in the broader specialty pharmaceutical and biotech space. Corcept maintains competitive advantage through its focused cortisol modulation platform and expanded pipeline of selective modulators with reduced side effect profiles compared to first-generation agents.
Industry Context
Corcept Therapeutics Incorporated operates in Biopharmaceutical / Specialty Pharma.
Key facts
Founded: 1998 · Headquarters: Redwood City, California · Revenue: $761.4M (2025)